



BIONOVELUS, INC.

A Nevada Corporation

2016 Annual Report

For Fiscal Year Ending December 31, 2016

This Annual Report contains forward-looking statements which reflect the Company's current views with respect to future events and financial performance. All statements other than statements of historical facts contained in this annual report, including statements regarding our future financial position, business strategy, and plans and objectives of management for future operations, are forward-looking statements. The words "believe," "expect," "anticipate," "intend," "estimate," "forecast," "project," and similar expressions identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations; any statements concerning proposed new products, services, developments, or the status of competitors; any statements regarding future economic conditions or performance; any statements of belief; any statements regarding the validity of our intellectual property; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements are subject to risks and uncertainties.

TO OUR SHAREHOLDERS,

We are pleased to present our 2016 Annual Report, and share our company's passion and enthusiasm for our planned future growth.

Following the completion of the reverse merger with Firstin Wireless in 2015, our organization maintained a clear focus on executing a strategy to get CR-10 to the market in Central America and bring BioNovelus closer and closer to its next phase: revenue.

At BioNovelus, we believe the most important contribution we can make to the ever-changing world and the challenges of food safety, health, and water cleanliness, is innovation – innovation not just in solutions, but in everything we do.

Some advances in bioscience are remarkable, and I believe we have a licensed product (and its variations) that can revolutionize the industry. "Organic" is more than a trend, it is a new way of living and in some cases, it even becomes a necessity. Our management is conscious of what we have, and we have a clear vision of how it can change the world. And in all our "startup moments", we live by this saying: "Nothing can stop an idea whose time has come."

Important milestones were achieved during 2016, providing confidence and reinforcing our passion and commitment to what we consider "bigger than a business", a safer green technology for our food, water, and health in this 21st century.

Our first mission in 2016 was to prove that our licensed organic biofungicide, CR-10, can kill the devastating fungus called "coffee leaf rust".

In Costa Rica, we started our pilot tests in February; these tests were successfully run for eight months in six different locations and altitudes, monitored by a cooperative of ten thousand coffee growers. These tests opened the door to negotiations with potential distributors. One even conducted his own trials in four additional coffee plantations. Among them was one of the preferred providers of Nespresso by Nestlé and another coffee grower was a supplier for Starbucks.

Guatemala took a little more time to open up, yet the country followed the lead of Costa Rica and took CR-10 into organic and traditional coffee growers for testing.

Meanwhile, BioNovelus has created a relationship with the two very active national Coffee Associations, Icafé in

Costa Rica, and Anacafé in Guatemala. Both are the prominent influencers of the local coffee industry. They researched CR-10 in depth in order to define how they could recommend it to their coffee growers members in the fight against coffee rust. This is an exciting collaboration as if the results of the tests are positive, CR-10 may be the only organic fungicide on the market to protect coffee plantations from the fungus.

In 2016, we also opened up testing other applications. We believe organic crop protection is key to better, cleaner, and healthier food supply.

As we move ahead in 2017, we will continue to actively explore potential green solutions to crucial environmental problems. We strive to make a positive impact in communities in Central America and ultimately if we expand our licensing around the world. We are enthusiastic about future additional applications and we continue to focus on building BioNovelus for sustained growth and to create long-term value for our shareholders, future customers, and employees.

Jean Ekobo,
President & CEO of BioNovelus Inc.

1) The exact name of the issuer and its predecessor (if any)

BioNovelus, Inc.

Firstin Wireless Technology, Inc. (until May 15, 2015)

Formerly Passionate Pet, Inc. (until January 31, 2013)

2) The address of the issuer's principal executive offices

275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel.: 1(888)924-6668
Website: <http://bionovelus.com>

IR Contact
Anthony Parkinson
BioNovelus Inc.
275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel.: 1(305)987-9107
Email: investor.relations@bionovelus.com

3) Security Information

Trading Symbol: ONOV
Exact title and class of securities outstanding: Common CUSIP:
09073X100
Par or Stated Value: \$0.001
Total shares authorized: 500,000,000 as of: December 31, 2016

Total shares outstanding: 91,837,699 as of: December 31, 2016

Exact title and class of securities outstanding: Preferred CUSIP: None

Par or Stated Value: \$0.001

Total shares authorized: 10,000,000 as of: December 31, 2016

Total shares outstanding: 10,000,000 as of: December 31, 2016

Transfer Agent Natco

Nevada Agency and Transfer

Company

50 West Liberty Street, suite 880

Reno, NV, 89501

Phone: 775-322-0626

Fax: 775-322-5623

Email: tiffany@natco.org

Natco is registered with the Securities and Exchange Commission as a transfer agent pursuant to Section 17A(c) of the Exchange Act.

No restrictions on the transfer of security other than the standard SEC restrictions.

No trading suspension orders issued by the SEC in the past 12 months.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On January 22, 2013 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Passionate Pet, Inc. to Firstin Wireless Technology, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 250 basis which was effected on January 31, 2013. On March 30, 2015 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Firstin Wireless Technology, Inc. to BioNovelus, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 750 basis.

4) Issuance History

During the year 2015, the Company issued common shares as described below:

70,000,000 shares of common stock pursuant to the acquisition agreement with BioNovelus, Inc.

During the year 2016, the Company issued common shares as described below:

a) The Company has elected to compensate the followings people in shares of common stock instead of cash for services or salaries:

Marvin Clark:	2,000,000 shares for consulting (equivalent to \$200,000)
Jean Ekobo:	3,600,000 shares for two years of salary (equivalent to \$90,000 per year)
Nathalie Fournier Ekobo:	2,400,000 shares for two years of salary (equivalent to \$60,000 per year)
Ronald Gorlish:	200,000 shares for consulting (equivalent to \$10,000)
Ria Godoy:	300,000 shares for consulting (equivalent to \$30,000)
Mark R. Johnson:	165,453 shares for consulting (equivalent to \$22,850)
Frederick Taylor:	45,700 shares for consulting (equivalent to \$22,850)

Information regarding equity compensation plans has been approved by the board of directors and majority shareholders.

b) Private Offerings:

These offerings were conducted under Rule 4(2) of Securities Act of 1933.

All shares issued contained a restricted legend stating that the shares have not been registered under the Securities Act and this legend further set forth the restrictions on transferability and sale of the shares under the Securities Act.

Date	Name	Proceeds	Shares	Price per share
06/20/2016	Dr. Bed Almerico	25,000.00	250,000	\$ 0.100
08/02/2016	James Amagrande	3,150.00	10,000	\$ 0.315
09/19/2016	James Amagrande	4,560.00	30,000	\$ 0.152
10/17/2016	James Amagrande	2,940.00	42,000	\$ 0.070
12/06/2016	James Amagrande	2,400.00	40,000	\$ 0.060
12/19/2016	James Amagrande	5,000.00	105,000	\$ 0.048
05/19/2016	William J. Beran	2,000.00	200,000	\$ 0.010
09/26/2016	Damaio	1,000.00	5,715	\$ 0.175
05/04/2016	The Ralph & Ria Godoy Rev. Family Trust	10,000.00	1,000,000	\$ 0.010
06/16/2016	The Ralph & Ria Godoy Rev. Family Trust	10,000.00	80,000	\$ 0.125
06/16/2016	The Ralph & Ria Godoy Rev. Family Trust	10,000.00	80,000	\$ 0.125
07/26/2016	Shey Godoy	2,500.00	3,572	\$ 0.700
08/12/2016	Paul Michael Haradon	3,000.00	21,429	\$ 0.140
08/12/2016	Sheryl King	3,000.00	21,429	\$ 0.140
05/02/2016	Raymond LeBlanc	2,000.00	200,000	\$ 0.010
06/20/2016	Robert Magness	25,000.00	250,000	\$ 0.100
07/26/2016	Kathleen Malone	14,600.00	20,858	\$ 0.700
05/06/2016	Louis & Judith Manganiello	3,000.00	200,000	\$ 0.015
08/16/2016	Britt Marmo	1,000.00	8,334	\$ 0.120
08/16/2016	Cole Marmo	1,000.00	8,334	\$ 0.120
09/19/2016	Marmo, Bronwyn	4,560.00	30,000	\$ 0.152
12/06/2016	Marmo, Bronwyn	2,400.00	40,000	\$ 0.060
08/02/2016	Marmo, Bronwyn	2,520.00	8,000	\$ 0.315
12/19/2016	Marmo, Bronwyn	5,000.00	105,000	\$ 0.048

Date	Name	Proceeds	Shares	Price per share
05/03/2016	Mariella Raven	1,500.00	150,000	\$ 0.010
05/23/2016	Mariella Raven	1,500.00	150,000	\$ 0.010
07/26/2016	Reisig Trust Fund	2,000.00	2,858	\$ 0.700
08/05/2016	Selina Reisig	3,200.00	8,000	\$ 0.400
08/05/2016	Victor Reisig	5,000.00	12,500	\$ 0.400
07/08/2016	Gina Richmann	3,000.00	4,290	\$ 0.699
08/22/2016	Gina Richmann	2,000.00	10,000	\$ 0.200
09/26/2016	Glenda Rosado	3,000.00	17,143	\$ 0.175
06/20/2016	Rose Family Limited Partnership	20,000.00	133,335	\$ 0.150
10/07/2016	Rose Family Limited Partnership	15,000.00	272,728	\$ 0.055
12/28/2016	Rose Family Limited Partnership	10,000.00	200,000	\$ 0.050
07/26/2016	Therese Skelly	3,000.00	4,286	\$ 0.700
06/17/2016	Therese Skelly	10,000.00	14,400	\$ 0.694
	Therese Skelly	2,000.00	1,600	\$ 1.250
12/31/2016	Therese Skelly	16,986.42	25,000	\$ 0.679
07/25/2016	James Skelly Revocable Trust	3,031.43	35,713	\$ 0.085
05/17/2016	Joseph Daniel Szolowicz	10,000.00	1,000,000	\$ 0.010
06/16/2016	Joseph Daniel Szolowicz	10,000.00	80,000	\$ 0.125
10/11/2016	Joseph Daniel Szolowicz	15,000.00	272,728	\$ 0.055
06/20/2016	Karen Worrell	25,000.00	250,000	\$ 0.070
09/20/2016	Karen Worrell		100,000	\$ 0.300
		306,847.85	5,504,252.00	

5) Financial Statements

The Issuer is providing the following financial statements for the year ending December 31, 2016 and financial notes, both of which have been filed with OTC Markets on March 31, 2017. These unaudited financial statements and financial notes are incorporated by reference herein.

- A. Balance sheet
- B. Statement of income
- C. Statement of cash flows
- D. Financial notes.

6) Describe the Issuer's Business, Products and Services

The Company operated a retail pet and supply store in Irvine, California which ran its operations and also sold retail premium pet food, supplies and service to the general public, through a wholly owned subsidiary. The Company decided to dispose of its operating business primarily because it had incurred significant operating losses in each of the last two years as the operations could not generate enough revenues to satisfy the significant rent and occupancy costs. On July 31, 2012, the former CEO, John Dunn entered into an agreement with the Company to sell 100% of his interest in the Company and assume the net assets and liabilities of the wholly owned subsidiary. As a result, the subsidiary together with its assets and liabilities were wholly owned by Mr. Dunn.

On January 23, 2013, the Company entered into a Share Exchange Agreement with the Firstin Wireless Technology, Inc., a corporation formed under the laws of Canada (Firstin Canada), and the shareholders of Firstin Canada. Under the terms of this agreement, Firstin Canada became the wholly owned subsidiary of the Company. On April 22, 2015, the Company entered into an Amalgamation Agreement with BioNovelus, Inc., an Arizona corporation.


The following business description and discussion regarding products relates to the operations of BioNovelus, Inc.

A. Description of the issuer's business operations

BioNovelus, Inc. (US OTC Pink: ONOV)

BioNovelus is a Clean Tech company whose vision is to answer critical environmental problems and to replace harmful chemicals with eco-friendly and profitable technologies in respect to our planet. Its mission is to offer proprietary disruptive green technologies that are innovative, cost-effective solutions for BioNovelus' customers, and partners, and benefit the shareholders and the planet at large.

There is an urgent need to keep ahead of both current and future pathogens, viruses and bacteria as well their resistant superbugs, and invasive species. Current products, many of which are toxic, while effective against many of these dangerous microbes, are corrosive, unstable, dangerous for transportation and for the environment, and cannot prevent re-infection. At BioNovelus, we passionately believe that "in this 21st Century it is time for harmful toxic chemicals to finally be replaced by new generations of eco-friendly, effective, and economical solutions to treat our water and our food."



Purpose of Technology

The purpose of the technology known as "CR-10" is to replace toxic chemicals such as chlorine, bleach, bromine and triazol. Its usable form is non-toxic, non-corrosive and odorless, and it is more effective than other water sanitizers (especially in high temperatures). Test results prove it to be lethal agent to many fungi, spores, bacteria, virus, and other pathogens. Various laboratories and universities have validated the formula.

Path to Commercialization

Our strategy is to have a Business to Business Model.

We will offer distribution agreements to companies that are already serving the markets we target.

We will sell 'Exclusive Distribution' with sales minima.

We will support these distributors with marketing material, and sales training.

Our Manufacturer is based in Europe, and will work as a third party to provide us with product at fixed cost.

BioNovelus Inc. has opened in 2016 two subsidiaries in Central America: BioNovelus-Costa Rica SA, and BioNovelus-Guatemala SA.

We are in process of registering CR-10 as a disinfectant through the Ministry of Health in both countries. The process of registration as a biofungicide through the Ministry of Agriculture will follow.

B. The Company (originally "Passionate Pet Inc.") was incorporated in the State of Nevada in September 2010.

C. The Issuer's primary SIC Code is 2879.

D. The Issuer's fiscal year end date is December 31.

E. The Company's principal products or services, and their markets:

The Market

CR-10, Biofungicide on a Mission to Save the Arabica Coffee

At present, BioNovelus is focused on putting CR-10 to market in Central America and Columbia by selling it to distributors and/or consumers of fungicide and pesticide products for the control of coffee leaf rust, and coffee bean and cocoa bean conservation. Our license agreement for the CR-10 product is limited to Mexico, Central America and Columbia markets.

The global Coffee market has more than \$175 billion in consumption value per year and generates tens of billions of dollars in profits for investors, and millions of jobs in developed nations.

At BioNovelus, we are determined to help coffee growers keep the better tasting strain of the Arabica plant by fighting coffee rust through our "green" CR-10 instead of being forced to change to "hybrid" type plants.

Management strongly believes that our "green", biodegradable product is not only better for our environment but for people who enjoy the rich flavor that comes from Arabica coffee beans, whether organic or not, and for the people that work in the coffee industry at large.



Industry Overview

"Global biopesticides market was valued at USD 1.96 billion in 2015 and is expected to reach USD 4.17 billion by 2023, growing at a CAGR of 9.9% for the 2015-2023 period.

The major factors for the success of the biopesticides market are the increasing demand for organic foods and growing environmental regulation on the usage of chemical pesticides. The usage of biopesticides can greatly decrease the use of conventional pesticides without affecting crop yields in the Integrated Crop Management (ICM) and Integrated Pest Management (IPM) programs. Other factors such as environment friendliness, toxicity of crop protection products, new product offerings, innovative production practices, increased availability, and advent of new pests are fueling the market for biopesticides, globally.

Biopesticides are safe as they have high host specificity and are biodegradable in nature, whereas traditional chemical pesticides often affect a broad range of pests as well as mammalian species and birds. They are required in low concentration to control insects. Moreover, biopesticides are required in very small quantities, thus offering lower exposure. In addition, they decompose quickly, leaving almost no harmful residue, and allowing field re-entry almost immediately after application. Thus, all the above-mentioned factors are expected to fuel the growth of this market globally.

(...)

Stringent regulations for chemical based pesticides and increasing demand from organic products are boosting the demand for biopesticides."

Source: transparencymarketresearch.com/biopesticides-market.html

Coffee Leaf Rust Control

The coffee industry is the second largest commodity market in the world to the oil industry (Source: Business Insider).

Since the late 19th century, the coffee industry has been plagued by Coffee Rust or "Roya" (*Hemileia vastatrix*) a devastating fungus that attacks the Arabica plant. Billions of dollars and hundreds of thousands of industry jobs have been lost throughout Central America since 2012 to this Coffee Rust epidemic. (Source: ICafé 2016).

The entire coffee belt from Indonesia to Africa, to Central and South America to Vietnam and Asia is seeking a remedy to this Coffee Rust epidemic.

Different than Competition

Our potential customers use the TRIAZOL family products out of desperation. They are toxic chemicals with a relative efficiency. So, farmers sometimes have to put 4 to 12 applications per year.

The greatest advantage of CR-10 is that it works in 24 hours, and with only two to three applications; farmers don't have to wait 8 to 15 days to see the results, and they save on labor cost because of fewer applications. CR-10 effects last longer, it is not toxic to humans at recommended dosage, and it is biodegradable.

LA ROYA *Hemileia Vastatrix*, Coffee Rust



- A fungus that is a plague to the \$175 billion/year coffee industry (Dr. Craig Nessler, Texas A&M)
- Economic impact since 2012:
Over \$2.5 billion lost in Central America only (ICafé)
- "Coffee could be extinct by 2080" John Connor, Climate Institute Director (nrdc.org)

Crop Protection

"La Roya" *Hemileia Vastatrix* or Coffee Leaf Rust



- Tests started with CoopeAgri R.L. in February 2016 in Costa Rica. Full season of coffee rust was monitored
- 12 "Fincas" are testing CR-10 in Guatemala & Costa-Rica
- Tests to get certifications by ICafé and Anacafé (National coffee trade associations)
- Presentation of CR-10 to the coffee industry at Sintercafé - Nov. 2016
- Starbucks will start the test in 2017

COMPETITIVE ADVANTAGE

COMPETITION	BioNovelus CR-10
Toxic chemicals: Triazol or copper based products	Environmentally friendly ingredients
NOT biodegradable	100% biodegradable
Visible results in 8-12 days	Visible results in 24-48 hours
4-12 applications needed	2-3 applications needed Coffee plant is saved.
Toxic for Humans and Animals	Safe for Humans and Animals

MARKET SIZE

Country	Hectares of Coffee Plantations
Honduras	282,000 ha
Guatemala	276,500 ha
Costa Rica	93,800 ha
Nicaragua	126,200 ha
El Salvador	152,200 ha
México	680,000 ha
Colombia	980,000 ha
Total	2,591,200 ha


1 liter will treat 1 hectare. 3 Applications are recommended.

Urgent Need for a Solution

The problem of coffee leaf rust is not as publicized, yet it is a real threat to the production of coffee.

In 2013, there was a major increase in Roya across 11 countries from Mexico to Peru. The disease became an epidemic and the resulting crop losses pushed coffee prices to an all-time high. The governments of Costa Rica, Nicaragua, and Guatemala have all declared a state of emergency due to the Roya economic impact.

In 2015 and beginning of 2016, due to climate change, we see the magnitude of the epidemic. In Mexico and Central America coffee harvest have dropped their production between 30 to 80%.



CR-10 for Crop Protection and Other Target Markets

CR-10 is a proven, biodegradable, non-toxic solution that kills bacteria, fungi, and spores rapidly, safely, and effectively. It is a new generation of biofungicide with a unique mode of action. BioNovelus management believes that CR-10 has a broad range of uses in agricultural applications.

In addition to fighting fungal infections on crops, we also believe that CR-10 is well suited to protect flowers, fruits and vegetables, grains and beans, after harvest to prevent mold and rot.

It increases the shelf life, and makes shipping easier with less returned items. It can then easily be removed by washing with water in preparation for consumption.



More than a business, BioNovelus strives to make a difference in people's lives, and make our planet a better and safer place to live.



Achievements in 2016

- Signed Exclusive Distribution agreement with CR-10 manufacturer for Mexico, Central America and Colombia
- Received Positive laboratory tests on coffee rust (2015/2016)
- Monitored Positive tests in 12 coffee plantations in Guatemala and Costa-Rica
- Received Positive laboratory study on CR-10 toxicity level
- Created and registered BioNovelus Inc.'s first subsidiary company, BioNovelus-Costa Rica SA, based in San Jose, Costa Rica
- Created and registered BioNovelus Inc.'s second subsidiary company, BioNovelus-Guatemala SA, based in Guatemala City, Guatemala
- Signed Letter of Intention with distributor in Costa-Rica
- Created a team in Central America with two Sales Representative (managing each subsidiary), an Agronomist-Researcher specialized in organic product development, a local legal counsel and two local accountants
- Deposited files for registration of CR-10 in Guatemala (Ministry of Health, and Agriculture), Costa-Rica (Ministry of Health, and Agriculture), and USA (EPA)
- Passed the selection to be a resident of Center of Entrepreneurial Innovation (CEI), a prominent incubator specialized in biotech and bioscience companies in Phoenix (Resident since June 2016)
- Presented CR-10 for the first time to the coffee Industry at Sintercafé
- Initiated positive conversations with Starbucks to test CR-10 at their Costa-Rican research center/coffee farm, Hacienda Alsacia
- Obtained testing for CR-10 by the National Association of Costa Rican Coffee Growers, Icafé, and their Research department Cicafé in order to be recommended and promoted (after approval) by this organization
- Obtained testing for CR-10 by the National Association of Guatemalan Coffee Growers, Anacafé, in order to be recommended and promoted (after approval) by this organization
- Raised funding of \$300,000



7) Description of the Issuer's Facilities

The Company was selected to become a resident of the Center of Entrepreneurial Innovation (CEI), incubator in Phoenix, Arizona. The Company entered into a lease agreement for office space in the CEI on June 1, 2016 and expiring on May 31, 2018. The minimum monthly lease payments range from \$512 to \$548. Total rent expense for the year ended December 31, 2016 was \$3,344.



8) Officers, Directors, and Control persons

A. Names of Officers, Directors, and Control Persons.

Jean Ekobo, President, CEO, Chairman of the Board
Nathalie Fournier Ekobo, Marketing & Communications Director, Secretary, Board Member
Marvin Clark, Treasurer, Board Member
Joss Francheterre, Board member

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
None.
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
None.
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
None.
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.
None.

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity

securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Jean Ekobo and Nathalie Fournier Ekobo
c/o BioNovelus Inc.
275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034

9) Third Party Providers

Legal Counsel

Frederick F. Taylor
5030 E. Sunrise Dr.
Phoenix AZ 85044
Tel: (480)626-0170
Email: Fred.F.Taylor@gmail.com

Accountant or Auditor

Moffitt & Company
11811 North Tatum Blvd. Suite 2600
Phoenix, AZ 85028
Tel: (480)951-1416
Email: info@moffittandcompany.com

Investor Relations Consultant

Anthony Parkinson
c/o BioNovelus Inc.
275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel: (305)987-9107
Email: investor.relations@bionovelus.com

Other Advisor:

Mark Johnson
B2B CFO
c/o BioNovelus Inc.
275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel: (602)882-3086
Email: mjohnson@b2bcfo.com

Other Advisor:

Stephen Boatwright
Kennedy and Gallagher PA
2575 East Camelback Road
Phoenix, Arizona, 85016
Tel: 602-530-8000
Fax: 602-530-8500
Email: steve.boatwright@gknet.com

10) Issuer Certification

I, Jean Ekobo, certify that:

1. I have reviewed this Annual Report of BioNovelus, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: Friday, March 31, 2017

A handwritten signature in dark ink, appearing to read 'Ekobo', is written over a horizontal line. The signature is stylized with a large initial 'E' and a trailing flourish.

Jean Ekobo, President and CEO, BioNovelus, Inc.